A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis
← catalyst calendarNCT06260709 · readout in 559 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
80estimated
Sites
35
Countries
Canada, Czechia, France +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-02-20 | actual | When the study began enrolling |
| Primary completion | 2028-02-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-08-15 | estimated | The whole study's end, after follow-up |
| First posted | 2024-02-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Intervention
- Drug: NNC6019-0001
Primary outcome
what the primary-completion date above is the date OFNumber of Treatment Emergent Adverse Events
measured From baseline (week 0) up to visit 39 (week 156)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed